- 询价
- 2025年12月30日
15 年金牌会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 相关疾病：
其他疾病
- 器官来源：
乳房
- ATCC Number：
CRL-2335™
- 年限：
TNM stage IIB, grade 2
- 物种来源：
人
- 是否是肿瘤细胞：
1
- 库存：
大量
- 生长状态：
贴壁生长
- 运输方式：
冻存运输
- 细胞形态：
上皮样
| Designations: | HCC1806 | ||
| Depositors: | AF Gazdar, AK Virmani | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent, The line grows as attached medium-sized epithelial cells without floating cells. | ||
| Organism: | Homo sapiens | ||
| Morphology: | epithelial |
||
| Source: | Organ: mammary gland; breast Tumor Stage: TNM stage IIB, grade 2 Disease: primary acantholytic squamous cell carcinoma |
||
| Cellular Products: | Epithelial glycoprotein 2 [EGP2]; cytokeratin 19 | ||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Restrictions: | The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935. | ||
| Applications: | The cells are poorly differentiated. HCC1806 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR). The cells are negative for expression of Her2-neu and for expression of p53. |
||
| Receptors: | estrogen receptor, negative progesterone receptor, negative |
||
| Oncogene: | her2/neu -, p53 - | ||
| Cytogenetic Analysis: | Number of cells examined = 59; Modal Chromosome Number = 75 with a range of 65 to 79; Polyploidy Rate = 22% | ||
| Age: | 60 years | ||
| Gender: | female | ||
| Ethnicity: | Black | ||
| Comments: | The HCC1806 cell line was initiated on July 31, 1995, and took 10 months to establish. The tumor was classified as a TNM Stage IIB, grade 2, acantholytic squamous carcinoma with no lymph node metastasis. There was no family history of breast cancer. The cells are poorly differentiated. The cells are negative for expression of Her2-neu and for expression of p53. HCC1806 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR). The cells are homozygous for deletions in the FHIT gene at 3p14.2. |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C |
||
| Subculturing: | Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended Medium Renewal: Every 2 to 3 days Remove medium, rinse with 0.25% trypsin, 0.03% EDTA solution, add an additional 1 to 2 ml of trypsin solution and allow the flask to set at room temperature (or incubate at 37C) until cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. |
||
| Preservation: | Culture medium, 95%; DMSO, 5% | ||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 |
||
| References: | 32258: Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768 38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771 |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验相关实验
Direct DNA Injection (p53) into HCC Tumors
Liver tumors, specially HCC, are among the most common malignancies in the world, and their annual world incidence is about 250,000 cases, with a male to female ratio 4:1 (1 ). HCC is one of the most important neoplasms in tropical
基于阻抗的rtca细胞分析技术应用--Transwell侵袭实验
细胞 (MCF-7和HCC1806) 转移疗效的。 研究者通过比较划痕处理后细胞迁移的趋势和速度，发现Maestro Z系统能够轻松地将两种肿瘤细胞系的差别区分开来。HCC1806细胞相对于MCF-7而言有更强的迁移能力, 这点能够和临床上观察到的三阴乳腺癌肿瘤细胞的高转移能力相呼应。此外，她们还发现MaestroZ系统对于不同抗转移MCP在作用效应和动态上的微小差别很敏感，证实了它在评估抗转移治疗疗效方面的价值。若要了解更多，可参考：（page_2 - (axionbio.cn)）
文献速递：全面液体分析循环肿瘤DNA和蛋白质生物标志物为评估预后带来新的可能
研究背景 肝细胞癌（HCC）被认为是中国癌症相关死亡率的第三大原因。尽管手术是治疗HCC的较佳选择，但由于缺乏早期症状，大多数患者在癌症晚期才被诊断出来，因此肿瘤复发的风险很高。识别可能复发的患者并给予对应的辅助治疗，仍然是一个临床难题。循环肿瘤DNA（ctDNA），也可称为肿瘤衍生的细胞游离DNA，包含有关肿瘤基因组图谱的全面信息，包括单核苷酸变异（SNVs）、拷贝数变异（CNVs）和表观遗传变异。将ctDNA与HCC中的传统血清蛋白生物标志物结合将为无创监测实时肿瘤进展提供新的可能。
技术资料暂无技术资料 索取技术资料
HCC1806
询价
